{"success":true,"data":{"pressRelease":{"id":"56271","rtpr_id":"nPn4gC4Cza","ticker":"WGS","exchange":"NASDAQ","all_tickers":["WGS"],"title":"GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - Hagens Berman","author":"PR Newswire","published_at":"2026-06-05T12:48:00.030Z","article_body":"GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - Hagens Berman\n\nPR Newswire\n\nSAN FRANCISCO, June 5, 2026\n\nSAN FRANCISCO, June 5, 2026 /PRNewswire/ -- GeneDx Holdings (NASDAQ: WGS)\nfaces a securities class action after the price of the company's stock\ncratered $33.42 (-49%) on May 5, 2026 in response to the company's disastrous\nQ1 2026 earnings report. The lawsuit seeks to represent investors who\npurchased shares of GeneDx common stock between April 16, 2025 and May 4,\n2026.\n\nNational shareholder rights law firm Hagens Berman is investigating claims\nthat GeneDx violated the federal securities laws. The firm urges GeneDx\ninvestors who suffered significant losses to contact the firm now to discuss\ntheir rights.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4704931-1&h=2668062363&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fwgs&a=contact+the+firm+now+to+discuss+their+rights.)\n\nClass Period: Apr. 16, 2025 – May 4, 2026\nLead Plaintiff Deadline: Aug. 3, 2026\nVisit: www.hbsslaw.com/investor-fraud/wgs\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4704931-1&h=2544093294&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fwgs&a=www.hbsslaw.com%2Finvestor-fraud%2Fwgs)\n\nContact the Firm Now: WGS@hbsslaw.com (mailto:WGS@hbsslaw.com)\n                                         844-916-0895\n\nGeneDx Holdings Corp. (WGS) Securities Class Action:\n\nBackground\n\nGeneDx operates a data-driven clinical diagnostics business model focused on\nrare and ultra-rare disease testing, emphasizing its whole genome sequencing\nand whole exome sequencing tests as primary growth drivers.\n\nThe company derives the bulk of its revenue from clinical diagnostic testing,\nbilling payers for ordering genome and exome tests, and emphasizes to\ninvestors the importance of its average reimbursement rate (\"ARR\") metric to\ngauge financial performance.\n\nGeneDx has touted its genome and exome growth and its \"consistent trend of\nacceleration.\" The company also emphasized the durability of its ARR which was\n$3750 in 2025, and which management conveyed in February (5 weeks into Q1)\nwould be flat for 2026. Also important to investors, management stressed that\ngenome and exome 2026 revenue and volume growth would be 33% to 35% with a\n\"baseline\" of 33% for Q1 2026.\n\nIn a move toward a hybrid diagnostic business model and capturing\ninternational business, on May 5, 2025, GeneDx acquired Fabric Genomics for\nabout $33.2 million cash. The company said this would expand the company's\naddressable market with multiple scalable revenue streams and \"transform[]\nstatic data into a dynamic, recurring revenue-generating platform – driving\ngrowth through software margins and high-leverage interpretation services\nacross geographies and clinical use cases.\"\n\nThe Complaint and Revelations\n\nThe complaint alleges that GeneDx made false and misleading statements and did\nnot disclose that the company misled investors about the importance of Fabric\nGenomics, that its margins would suffer, its ARRs were not durable and, as a\nresult, its gross margins would decline.\n\nOn May 4, 2026, the company's growth narrative abruptly and negatively\nchanged. That day, GeneDx reported dismal Q1 2026 financial results which\nincluded a massive tenfold increase in net loss compared to the prior year\nperiod. The Fabric Genomics business (which reported a $2.5 million revenue\nmiss) was the largest contributor to the loss, as GeneDx recorded impairment\ncharges related to the unit totaling $31.2 million, or about 94% of the cash\npaid for it just one year ago.\n\nIn addition, and in contrast to its February assurances, GeneDx's ARR fell\nabout $200 short, a surprise blamed on a huge, adverse change in product mix\ntoward genome whose ARR was only half that of exome. The company also said\nthat exome and genome revenue growth would be \"at least 20%,\" substantially\nlower than it said in February. As a result of GeneDx's changed growth\nnarrative, the company slashed 2026 revenue guidance by 12%.\n\n\"We're investigating whether GeneDx may have intentionally or recklessly\nmisled investors about Fabric's real value to the company, the key changes in\nits product mix that have dramatically reduced their growth expectations, and\nwhen management first knew of the product shift,\" said Reed Kathrein, the\nHagens Berman partner leading the firm's investigation.\n\nIf you invested in GeneDx and have substantial losses, or have knowledge that\nmay assist the firm's investigation, submit your losses now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4704931-1&h=2192453452&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fwgs&a=submit+your+losses+now)\n»\n\nIf you'd like more information and answers to other frequently asked questions\nabout the case and the firm's GeneDx investigation, read more »\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4704931-1&h=2103399084&u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Fgenedx-holdings-corp-wgs-securities-class-action&a=read+more+%C2%BB)\n\nWhistleblowers: Persons with non-public information regarding GeneDx should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email WGS@hbsslaw.com (mailto:WGS@hbsslaw.com) .\n\nAbout Hagens Berman\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4704931-1&h=3880775175&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=About+Hagens+Berman)\n\nHagens Berman is a global plaintiffs' rights complex litigation firm focusing\non corporate accountability. The firm is home to a robust practice and\nrepresents investors as well as whistleblowers, workers, consumers and others\nin cases achieving real results for those harmed by corporate negligence and\nother wrongdoings. Hagens Berman's team has secured more than $2.9 billion in\nthis area of law. More about the firm and its successes can be found\nat hbsslaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4704931-1&h=49742654&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=hbsslaw.com)\n. Follow the firm for updates and news at @ClassActionLaw\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4704931-1&h=946523184&u=https%3A%2F%2Fwww.twitter.com%2FClassActionLaw&a=%40ClassActionLaw)\n.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/genedx-holdings-wgs-faces-securities-class-action-after-49-drop-94-write-off-related-to-fabric-genomics-acquisition--hagens-berman-302792285.html\n(https://www.prnewswire.com/news-releases/genedx-holdings-wgs-faces-securities-class-action-after-49-drop-94-write-off-related-to-fabric-genomics-acquisition--hagens-berman-302792285.html)\n\nSOURCE Hagens Berman Sobol Shapiro LLP\n\n\n\nReed Kathrein, 844-916-0895\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1117217/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg?id=OA2669939\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn4gC4Cza","title":"GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - Hagens Berman","author":"PR Newswire","ticker":"WGS","created":"2026-06-05T12:48:00.030Z","tickers":["WGS"],"exchange":"NASDAQ","article_body":"GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition - Hagens Berman\n\nPR Newswire\n\nSAN FRANCISCO, June 5, 2026\n\nSAN FRANCISCO, June 5, 2026 /PRNewswire/ -- GeneDx Holdings (NASDAQ: WGS)\nfaces a securities class action after the price of the company's stock\ncratered $33.42 (-49%) on May 5, 2026 in response to the company's disastrous\nQ1 2026 earnings report. The lawsuit seeks to represent investors who\npurchased shares of GeneDx common stock between April 16, 2025 and May 4,\n2026.\n\nNational shareholder rights law firm Hagens Berman is investigating claims\nthat GeneDx violated the federal securities laws. The firm urges GeneDx\ninvestors who suffered significant losses to contact the firm now to discuss\ntheir rights.\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4704931-1&h=2668062363&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fwgs&a=contact+the+firm+now+to+discuss+their+rights.)\n\nClass Period: Apr. 16, 2025 – May 4, 2026\nLead Plaintiff Deadline: Aug. 3, 2026\nVisit: www.hbsslaw.com/investor-fraud/wgs\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4704931-1&h=2544093294&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fwgs&a=www.hbsslaw.com%2Finvestor-fraud%2Fwgs)\n\nContact the Firm Now: WGS@hbsslaw.com (mailto:WGS@hbsslaw.com)\n                                         844-916-0895\n\nGeneDx Holdings Corp. (WGS) Securities Class Action:\n\nBackground\n\nGeneDx operates a data-driven clinical diagnostics business model focused on\nrare and ultra-rare disease testing, emphasizing its whole genome sequencing\nand whole exome sequencing tests as primary growth drivers.\n\nThe company derives the bulk of its revenue from clinical diagnostic testing,\nbilling payers for ordering genome and exome tests, and emphasizes to\ninvestors the importance of its average reimbursement rate (\"ARR\") metric to\ngauge financial performance.\n\nGeneDx has touted its genome and exome growth and its \"consistent trend of\nacceleration.\" The company also emphasized the durability of its ARR which was\n$3750 in 2025, and which management conveyed in February (5 weeks into Q1)\nwould be flat for 2026. Also important to investors, management stressed that\ngenome and exome 2026 revenue and volume growth would be 33% to 35% with a\n\"baseline\" of 33% for Q1 2026.\n\nIn a move toward a hybrid diagnostic business model and capturing\ninternational business, on May 5, 2025, GeneDx acquired Fabric Genomics for\nabout $33.2 million cash. The company said this would expand the company's\naddressable market with multiple scalable revenue streams and \"transform[]\nstatic data into a dynamic, recurring revenue-generating platform – driving\ngrowth through software margins and high-leverage interpretation services\nacross geographies and clinical use cases.\"\n\nThe Complaint and Revelations\n\nThe complaint alleges that GeneDx made false and misleading statements and did\nnot disclose that the company misled investors about the importance of Fabric\nGenomics, that its margins would suffer, its ARRs were not durable and, as a\nresult, its gross margins would decline.\n\nOn May 4, 2026, the company's growth narrative abruptly and negatively\nchanged. That day, GeneDx reported dismal Q1 2026 financial results which\nincluded a massive tenfold increase in net loss compared to the prior year\nperiod. The Fabric Genomics business (which reported a $2.5 million revenue\nmiss) was the largest contributor to the loss, as GeneDx recorded impairment\ncharges related to the unit totaling $31.2 million, or about 94% of the cash\npaid for it just one year ago.\n\nIn addition, and in contrast to its February assurances, GeneDx's ARR fell\nabout $200 short, a surprise blamed on a huge, adverse change in product mix\ntoward genome whose ARR was only half that of exome. The company also said\nthat exome and genome revenue growth would be \"at least 20%,\" substantially\nlower than it said in February. As a result of GeneDx's changed growth\nnarrative, the company slashed 2026 revenue guidance by 12%.\n\n\"We're investigating whether GeneDx may have intentionally or recklessly\nmisled investors about Fabric's real value to the company, the key changes in\nits product mix that have dramatically reduced their growth expectations, and\nwhen management first knew of the product shift,\" said Reed Kathrein, the\nHagens Berman partner leading the firm's investigation.\n\nIf you invested in GeneDx and have substantial losses, or have knowledge that\nmay assist the firm's investigation, submit your losses now\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4704931-1&h=2192453452&u=https%3A%2F%2Fwww.hbsslaw.com%2Finvestor-fraud%2Fwgs&a=submit+your+losses+now)\n»\n\nIf you'd like more information and answers to other frequently asked questions\nabout the case and the firm's GeneDx investigation, read more »\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4704931-1&h=2103399084&u=https%3A%2F%2Fwww.hbsslaw.com%2Fcases%2Fgenedx-holdings-corp-wgs-securities-class-action&a=read+more+%C2%BB)\n\nWhistleblowers: Persons with non-public information regarding GeneDx should\nconsider their options to help in the investigation or take advantage of the\nSEC Whistleblower program. Under the new program, whistleblowers who provide\noriginal information may receive rewards totaling up to 30 percent of any\nsuccessful recovery made by the SEC. For more information, call Reed Kathrein\nat 844-916-0895 or email WGS@hbsslaw.com (mailto:WGS@hbsslaw.com) .\n\nAbout Hagens Berman\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4704931-1&h=3880775175&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=About+Hagens+Berman)\n\nHagens Berman is a global plaintiffs' rights complex litigation firm focusing\non corporate accountability. The firm is home to a robust practice and\nrepresents investors as well as whistleblowers, workers, consumers and others\nin cases achieving real results for those harmed by corporate negligence and\nother wrongdoings. Hagens Berman's team has secured more than $2.9 billion in\nthis area of law. More about the firm and its successes can be found\nat hbsslaw.com\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4704931-1&h=49742654&u=https%3A%2F%2Fwww.hbsslaw.com%2F&a=hbsslaw.com)\n. Follow the firm for updates and news at @ClassActionLaw\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4704931-1&h=946523184&u=https%3A%2F%2Fwww.twitter.com%2FClassActionLaw&a=%40ClassActionLaw)\n.\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/genedx-holdings-wgs-faces-securities-class-action-after-49-drop-94-write-off-related-to-fabric-genomics-acquisition--hagens-berman-302792285.html\n(https://www.prnewswire.com/news-releases/genedx-holdings-wgs-faces-securities-class-action-after-49-drop-94-write-off-related-to-fabric-genomics-acquisition--hagens-berman-302792285.html)\n\nSOURCE Hagens Berman Sobol Shapiro LLP\n\n\n\nReed Kathrein, 844-916-0895\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1117217/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg?id=OA2669939\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-06-05T12:48:00.107303958Z","server_sent_at_ms":1780663680107},"received_at":"2026-06-05T12:48:00.159Z","source_url":"https://www.prnewswire.com/news-releases/genedx-holdings-wgs-faces-securities-class-action-after-49-drop-94-write-off-related-to-fabric-genomics-acquisition--hagens-berman-302792285.html"},"analysis":{"id":"45698","press_release_id":"56271","analysis_json":{"industry":{"label":"Health Care Providers & Services","sector":"Health Care"},"redFlags":[],"eventType":"legal_litigation","narrative":"Hagens Berman issued a shareholder solicitation regarding a securities class action against GeneDx Holdings (WGS).\n\nThe firm urges investors who purchased shares between April 16, 2025, and May 4, 2026, to contact them to discuss their rights.\n\nThe release references a 49% stock drop and a 94% write-off of the Fabric Genomics acquisition following Q1 2026 earnings, but contains no new disclosure from the company itself.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"customDimensions":{"arr_decline":"$200","stock_drop_pct":"-49%","stock_drop_usd":"$33.42","guidance_cut_pct":"12%","fabric_genomics_revenue_miss":"$2.5 million","fabric_genomics_writeoff_pct":"94%","fabric_genomics_writeoff_usd":"$31.2 million","fabric_genomics_acquisition_price":"$33.2 million"}},"quotedText":"We're investigating whether GeneDx may have intentionally or recklessly misled investors about Fabric's real value to the company, the key changes in its product mix that have dramatically reduced their growth expectations, and when management first knew of the product shift","namedEntities":{"people":[{"name":"Reed Kathrein","role":"Partner, Hagens Berman"}],"products":[],"companies":[{"name":"GeneDx Holdings Corp.","ticker":"WGS","relationship":"target"},{"name":"Hagens Berman Sobol Shapiro LLP","relationship":"plaintiff law firm"},{"name":"Fabric Genomics","relationship":"acquired subsidiary"}],"dollarAmounts":[{"amount":"$33.42","context":"stock price drop on May 5, 2026"},{"amount":"$33.2 million","context":"cash paid for Fabric Genomics acquisition"},{"amount":"$2.5 million","context":"Fabric Genomics revenue miss"},{"amount":"$31.2 million","context":"impairment charges related to Fabric Genomics"},{"amount":"$3750","context":"average reimbursement rate (ARR) in 2025"},{"amount":"$200","context":"shortfall in ARR vs February assurances"},{"amount":"$2.9 billion","context":"total recovered by Hagens Berman in this area of law"}]},"materialImpact":{"score":1,"reasoning":"This is a plaintiff law-firm solicitation issued by Hagens Berman. It contains no new disclosure from the issuer, no certified class, and no settlement. Per guardrails, such releases are scored as low-impact noise."},"tickerRelevance":{"others":[],"primary":"WGS"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"context":"references significant prior earnings miss and write-off, but release itself is marketing noise","tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Hagens Berman issued a shareholder solicitation regarding a securities class action against GeneDx Holdings (WGS).\n\nThe firm urges investors who purchased shares between April 16, 2025, and May 4, 2026, to contact them to discuss their rights.\n\nThe release references a 49% stock drop and a 94% write-off of the Fabric Genomics acquisition following Q1 2026 earnings, but contains no new disclosure from the company itself.","key_figures":{"customDimensions":{"arr_decline":"$200","stock_drop_pct":"-49%","stock_drop_usd":"$33.42","guidance_cut_pct":"12%","fabric_genomics_revenue_miss":"$2.5 million","fabric_genomics_writeoff_pct":"94%","fabric_genomics_writeoff_usd":"$31.2 million","fabric_genomics_acquisition_price":"$33.2 million"}},"named_entities":{"people":[{"name":"Reed Kathrein","role":"Partner, Hagens Berman"}],"products":[],"companies":[{"name":"GeneDx Holdings Corp.","ticker":"WGS","relationship":"target"},{"name":"Hagens Berman Sobol Shapiro LLP","relationship":"plaintiff law firm"},{"name":"Fabric Genomics","relationship":"acquired subsidiary"}],"dollarAmounts":[{"amount":"$33.42","context":"stock price drop on May 5, 2026"},{"amount":"$33.2 million","context":"cash paid for Fabric Genomics acquisition"},{"amount":"$2.5 million","context":"Fabric Genomics revenue miss"},{"amount":"$31.2 million","context":"impairment charges related to Fabric Genomics"},{"amount":"$3750","context":"average reimbursement rate (ARR) in 2025"},{"amount":"$200","context":"shortfall in ARR vs February assurances"},{"amount":"$2.9 billion","context":"total recovered by Hagens Berman in this area of law"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-05T12:48:27.278Z","global_importance":15,"audience_relevance":10,"importance_components":{"context":"references significant prior earnings miss and write-off, but release itself is marketing noise","tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":27110,"modelName":"george-droid-qwen-72b"}}